You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Details for Patent: RE47739

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE47739 protect, and when does it expire?

Patent RE47739 protects IBRANCE and is included in two NDAs.

This patent has seventy-three patent family members in forty-nine countries.

Summary for Patent: RE47739

Title:	2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Abstract:	The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4) ##STR00001##
Inventor(s):	Barvian; Mark (Ann Arbor, MI), Booth; Richard John (Ann Arbor, MI), Quinn, III; John (Ann Arbor, MI), Repine; Joseph Thomas (Ann Arbor, MI), Sheehan; Derek J. (Dexter, MI), Toogood; Peter Lawrence (Ann Arbor, MI), Vanderwel; Scott Norman (Ann Arbor, MI), Zhou; Hairong (Ann Arbor, MI)
Assignee:	Warner-Lambert Company LLC (New York, NY)
Application Number:	16/048,143
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent RE47739

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-001	Nov 1, 2019		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent RE47739

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1767	⤷ Try a Trial
Argentina	038814	⤷ Try a Trial
Argentina	083686	⤷ Try a Trial
Austria	314370	⤷ Try a Trial
Australia	2003237009	⤷ Try a Trial
Brazil	0307057	⤷ Try a Trial
Brazil	122016021801	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.